CANF Stock Catalyst: Can-Fite BioPharma Ltd. Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology

Jun 26, 2026 · 7:01am ET

The allowance enhances the company's intellectual property portfolio.

Max move

+36.1%

High of day $4.49

Sparker timei

7:01am ET

CANF · Jun 26, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Can-Fite BioPharma Ltd. (NYSE: CANF) announced that it has secured a patent allowance in Japan for its Namodenoson compound, specifically for its application in anti-obesity technology. This development strengthens the company's intellectual property portfolio in the Japanese market.

The allowance pertains to the use of Namodenoson in treating obesity, a significant addition to Can-Fite's existing patents. With 811,772 shares in free float and 2,142,547 shares outstanding, this intellectual property enhancement could have strategic implications for the company's future market positioning.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time CANF sparks.

Download Sniper App →

Catch the next CANF-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →